Ever heard of BioMed X? If you are curious about innovation crowdsourcing, you should definitely check them out. BioMed X is one of the first companies to use crowdsourcing to discover new innovation in the life sciences, through which a biotech team has been assembled and financed to develop a new treatment for COPD.
Chronic obstructive pulmonary disease (COPD) is a treatable but incurable lung disease affecting 210 million people worldwide, predicted to become the 3rd leading cause of death by 2030. In the fight against this multi-factorial disease, the German pharmaceutical group Boehringer Ingelheim has maintained its leading position for over 90 years. But when it comes to finding innovative approaches to tackle the disease, this pharma giant’s model rapidly falls short.
That’s where BioMed X comes forward with its crowdsourcing solution. BioMed X takes this problem of big pharma companies like Boehringer, and publicly shares it with universities all around the world to recruit young talented individuals to find a solution. The best of the were selected for a bootcamp in the hope of winning a two to four year fellowship at the BioMed X innovation center,